Orthogon Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
45 Dan Rd Ste 126, Canton, Massachusetts...Phone Number
(339) 502-8643Website
www.orthogontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Orthogon Therapeutics
Orthogon Therapeutics is a privately held drug discovery and development company with a portfolio of infectious disease assets, including antiviral therapeutics. Its lead program is a first-in-class, orally administrable small-molecule inhibitor of BK virus replication, a common virus affecting transplant patients. The company specializes in discovering small-molecule therapies targeting difficult viral diseases, particularly in immunocompromised patients, and develops innovative drug platforms to address unmet medical needs in infectious diseases through research-driven pharmaceutical development.Explore more
Orthogon Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orthogon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Orthogon Therapeutics has new funding data
Earning: See what the market has to say on Orthogon Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Orthogon Therapeutics
Check if Orthogon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Orthogon Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Orthogon Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Orthogon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Orthogon Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Orthogon Therapeutics
Compare insights from companies similar to Orthogon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Orthogon Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Orthogon Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Orthogon Therapeutics.
Orthogon Therapeutics financials insights
Gather financial insights about Orthogon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$4.4M
2021
Debt
$84K
Private Equity
$8M
2024
Other Financing Round
$5M
2026
Unspecified
$11M
Orthogon Therapeutics Tech Stack
A closer look at the technologies used by Orthogon Therapeutics
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Funding
Orthogon Therapeutics News & Media
Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus
CANTON, Mass.--(BUSINESS WIRE)-- #BKVAN--Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients. The company has successfully developed small molecule drugs that directly target viral proteins essential to the polyomavirusOrthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M ...
CANTON, Mass.--(BUSINESS WIRE)--Jul 24, 2023--Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics LLC, a trailblazer in the field of antiviral therapeutics, today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a pivotal technical milestone that has unlocked an additional $3M from its dedicated syndicate of healthcare investors. This wraps up a $6M financing over the past year and brings Orthogon's total raise to a formidable $18.5M. "We're celebrating this scientific achievemFormer Novartis Executive Dr. Marie Lindner Joins Orthogon Therapeutics’ Board of Directors
CANTON, Mass.--(BUSINESS WIRE)--Orthogon announces the appointment of a seasoned BioPharma executive and former VC to its board of directors
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orthogon Therapeutics
Sign Up For FreeTo access detailed company insights
Orthogon Therapeutics is a privately held drug discovery and development company with a portfolio of infectious disease assets, including antiviral therapeutics. Its lead program is a first-in-class, orally administrable small-molecule inhibitor of BK virus replication, a common virus affecting transplant patients. The company specializes in discov... Read More
